Mylan Resolves Shire Suit Over Generic Fosrenol

Law360, New York (June 22, 2011, 6:34 PM EDT) -- Shire US Inc. on Tuesday ended its patent infringement suit in New York against Mylan Inc. and Matrix Laboratories Ltd. over a generic version of the drug Fosrenol, which reduces phosphate levels in the blood of kidney disease patients. 

U.S. District Judge Paul Gardephe dismissed all claims and counterclaims in the case without prejudice as per a stipulation motion from the parties, which agreed to pay their own attorneys' fees and costs. 

The sides also said that that a stay on U.S. Food and Drug Administration...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.